NCT07426380
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 12 words
- Trial completed
- Primary and study completion dates changed from estimate of Oct 2026 to Oct 6, 2026
- Minor Enrollment closed, study ongoing
- Site details revised at 2 of 2 sites
- Minor Site details revised at 1 of 2 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 2026 to Feb 24, 2026
- Site details revised at 2 of 2 sites
- Minor Study title revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
Timeframe: Predose on Day 1 up to Day 71
PK: Maximum Observed Drug Concentration (Cmax) of LY3841136
Timeframe: Predose on Day 1 up to Day 71
Arms and interventions
Eloralintide (Group 1)Experimental
Eloralintide administered subcutaneously (SC) in a control group of participants with normal renal function
Eloralintide (Groups 2 and 3)Experimental
Eloralintide administered SC in groups of participants with impaired renal function
Eloralintide (Group 3)Experimental
Eloralintide administered SC in a group of participants with end-stage renal disease (ESRD) on stable hemodialysis
Drugs: LY3841136
Sites
2 sites in 1 country